Deletion of Gpr55 Results in Subtle Effects on Energy Metabolism, Motor Activity and Thermal Pain Sensation.

by Mikael Bjursell, Erik Ryberg, Tingting Wu, Peter J Greasley, Mohammad Bohlooly-Y, Stephan Hjorth
Published 2016-01-01

Impact of CKD Progression on Cardiovascular Disease Risk in a Contemporary UK Cohort of Individuals With Diabetes

by Claudia S. Cabrera, Alison S. Lee, Marita Olsson, Volker Schnecke, Klara Westman, Marcus Lind, Peter J. Greasley, Stanko Skrtic
Published 2020-10-01

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling

by Victor Sokolov, Tatiana Yakovleva, Lulu Chu, Weifeng Tang, Peter J. Greasley, Susanne Johansson, Kirill Peskov, Gabriel Helmlinger, David W. Boulton, Robert C. Penland
Published 2020-04-01

Data from a pooled post hoc analysis of 14 placebo-controlled, dapagliflozin treatment studies in patients with type 2 diabetes with and without anemia at baseline

by Bergur V. Stefánsson, Hiddo J.L. Heerspink, David C. Wheeler, C. David Sjöström, Peter J. Greasley, Peter Sartipy, Valerie Cain, Ricardo Correa-Rotter
Published 2021-08-01

Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus

by Alan S. Go, Jingrong Yang, Thida C. Tan, Claudia S. Cabrera, Bergur V. Stefansson, Peter J. Greasley, Juan D. Ordonez, for the Kaiser Permanente Northern California CKD Outcomes Study
Published 2018-06-01

Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study

by Andrew Whittaker, Åsa M. Kragh, Judith Hartleib‐Geschwindner, Muna Albayaty, Anna Backlund, Peter J. Greasley, Maria Heijer, Magnus Kjaer, Pablo Forte, Robert Unwin, Linda Wernevik, Hans Ericsson
Published 2020-03-01